Haploidentical Stem Cell Transplantation and Stem Cell Mobilization for Relapsed Neuroblastoma
Received Date: Jul 03, 2022 / Published Date: Jul 30, 2022
Abstract
Despite autologous stem cell transplantation, paediatric patients with refractory or relapsed metastatic neuroblastoma (NBL) have a poor prognosis (SCT). We tested this strategy in kids with very high risk NBL since allogeneic SCT from a haploidentical donor has an impressive alloreactive effect in leukaemia patients. Data from two prospective phase I/II trials were examined. A median of 17 106/kg T/B cell-depleted CD34+ stem cells with 68 103/kg residual T cells and 107 106/kg natural killer cells were given to 26 patients with refractory (n = 5), metastatic relapsed (n = 20), or locally relapsed (n = 1) MYCN-positive NBL. Melphalan, fludarabine, thiotepa, OKT3, and a brief course of mycophenolate mofetil were all included in the conditioning regimen. 96 percent of the patients experienced engraftment. overall survival and event-free Survival rates at 5 years were 19 and 23%, respectively. The lone fatality was brought about by progression or a subsequent relapse; no transplantation-related mortality was noted.
Keywords: Melphalan; Fludarabine; Thiotepa; Mycophenolate
Citation: Holzer M (2022) Haploidentical Stem Cell Transplantation and Stem Cell Mobilization for Relapsed Neuroblastoma. J Clin Exp Transplant 7: 140. Doi: 10.4172/2475-7640.1000140
Copyright: © 2022 Holzer M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
天美传媒 Access Journals
Article Tools
Article Usage
- Total views: 704
- [From(publication date): 0-2022 - Jan 27, 2025]
- Breakdown by view type
- HTML page views: 516
- PDF downloads: 188